Intrinsic value of AtriCure - ATRC

Previous Close

$22.37

  Intrinsic Value

$0.47

stock screener

  Rating & Target

str. sell

-98%

  Value-price divergence*

-82%

Previous close

$22.37

 
Intrinsic value

$0.47

 
Up/down potential

-98%

 
Rating

str. sell

 
Value-price divergence*

-82%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of ATRC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  19.23
  13.90
  13.01
  12.21
  11.49
  10.84
  10.26
  9.73
  9.26
  8.83
  8.45
  8.10
  7.79
  7.51
  7.26
  7.04
  6.83
  6.65
  6.48
  6.34
  6.20
  6.08
  5.97
  5.88
  5.79
  5.71
  5.64
  5.58
  5.52
  5.47
  5.42
Revenue, $m
  155
  177
  200
  224
  250
  277
  305
  335
  366
  398
  432
  467
  503
  541
  580
  621
  663
  707
  753
  801
  851
  902
  956
  1,012
  1,071
  1,132
  1,196
  1,263
  1,332
  1,405
  1,481
Variable operating expenses, $m
 
  210
  236
  264
  293
  324
  356
  389
  425
  461
  499
  528
  569
  612
  657
  703
  751
  801
  853
  907
  963
  1,022
  1,083
  1,146
  1,213
  1,282
  1,354
  1,430
  1,509
  1,591
  1,677
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  186
  210
  236
  264
  293
  324
  356
  389
  425
  461
  499
  528
  569
  612
  657
  703
  751
  801
  853
  907
  963
  1,022
  1,083
  1,146
  1,213
  1,282
  1,354
  1,430
  1,509
  1,591
  1,677
Operating income, $m
  -31
  -34
  -37
  -40
  -44
  -47
  -51
  -55
  -59
  -63
  -68
  -62
  -67
  -72
  -77
  -82
  -88
  -94
  -100
  -106
  -112
  -119
  -126
  -134
  -142
  -150
  -158
  -167
  -176
  -186
  -196
EBITDA, $m
  -21
  -18
  -21
  -23
  -26
  -29
  -32
  -35
  -38
  -41
  -45
  -48
  -52
  -56
  -60
  -64
  -69
  -73
  -78
  -83
  -88
  -93
  -99
  -105
  -111
  -117
  -124
  -131
  -138
  -146
  -153
Interest expense (income), $m
  2
  3
  4
  5
  6
  8
  9
  10
  12
  14
  15
  17
  19
  21
  23
  25
  27
  29
  31
  33
  36
  38
  41
  44
  47
  50
  53
  56
  60
  63
  67
Earnings before tax, $m
  -33
  -37
  -41
  -45
  -50
  -55
  -60
  -65
  -71
  -77
  -83
  -79
  -85
  -92
  -99
  -107
  -114
  -122
  -131
  -139
  -148
  -158
  -168
  -178
  -188
  -200
  -211
  -223
  -236
  -249
  -263
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -33
  -37
  -41
  -45
  -50
  -55
  -60
  -65
  -71
  -77
  -83
  -79
  -85
  -92
  -99
  -107
  -114
  -122
  -131
  -139
  -148
  -158
  -168
  -178
  -188
  -200
  -211
  -223
  -236
  -249
  -263

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  44
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  276
  264
  299
  335
  374
  414
  457
  501
  547
  596
  646
  698
  753
  809
  868
  929
  993
  1,059
  1,127
  1,199
  1,273
  1,351
  1,431
  1,516
  1,603
  1,695
  1,790
  1,890
  1,994
  2,103
  2,217
Adjusted assets (=assets-cash), $m
  232
  264
  299
  335
  374
  414
  457
  501
  547
  596
  646
  698
  753
  809
  868
  929
  993
  1,059
  1,127
  1,199
  1,273
  1,351
  1,431
  1,516
  1,603
  1,695
  1,790
  1,890
  1,994
  2,103
  2,217
Revenue / Adjusted assets
  0.668
  0.670
  0.669
  0.669
  0.668
  0.669
  0.667
  0.669
  0.669
  0.668
  0.669
  0.669
  0.668
  0.669
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
  0.668
Average production assets, $m
  84
  96
  108
  121
  135
  150
  165
  181
  198
  216
  234
  253
  273
  293
  314
  336
  359
  383
  408
  434
  461
  489
  518
  549
  580
  614
  648
  684
  722
  762
  803
Working capital, $m
  57
  17
  19
  22
  24
  27
  30
  32
  35
  39
  42
  45
  49
  52
  56
  60
  64
  69
  73
  78
  83
  88
  93
  98
  104
  110
  116
  122
  129
  136
  144
Total debt, $m
  39
  52
  67
  84
  102
  120
  140
  160
  181
  203
  226
  250
  275
  301
  328
  356
  385
  415
  446
  479
  513
  548
  585
  624
  664
  706
  749
  795
  842
  892
  944
Total liabilities, $m
  108
  121
  136
  153
  171
  189
  209
  229
  250
  272
  295
  319
  344
  370
  397
  425
  454
  484
  515
  548
  582
  617
  654
  693
  733
  775
  818
  864
  911
  961
  1,013
Total equity, $m
  168
  144
  162
  182
  203
  225
  248
  272
  297
  323
  351
  379
  409
  440
  471
  505
  539
  575
  612
  651
  691
  733
  777
  823
  871
  920
  972
  1,026
  1,083
  1,142
  1,204
Total liabilities and equity, $m
  276
  265
  298
  335
  374
  414
  457
  501
  547
  595
  646
  698
  753
  810
  868
  930
  993
  1,059
  1,127
  1,199
  1,273
  1,350
  1,431
  1,516
  1,604
  1,695
  1,790
  1,890
  1,994
  2,103
  2,217
Debt-to-equity ratio
  0.232
  0.360
  0.420
  0.460
  0.500
  0.530
  0.560
  0.590
  0.610
  0.630
  0.640
  0.660
  0.670
  0.680
  0.700
  0.700
  0.710
  0.720
  0.730
  0.740
  0.740
  0.750
  0.750
  0.760
  0.760
  0.770
  0.770
  0.770
  0.780
  0.780
  0.780
Adjusted equity ratio
  0.534
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543
  0.543

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -33
  -37
  -41
  -45
  -50
  -55
  -60
  -65
  -71
  -77
  -83
  -79
  -85
  -92
  -99
  -107
  -114
  -122
  -131
  -139
  -148
  -158
  -168
  -178
  -188
  -200
  -211
  -223
  -236
  -249
  -263
Depreciation, amort., depletion, $m
  10
  16
  16
  17
  18
  18
  19
  20
  21
  22
  23
  13
  14
  16
  17
  18
  19
  20
  22
  23
  24
  26
  27
  29
  31
  32
  34
  36
  38
  40
  42
Funds from operations, $m
  -20
  -21
  -25
  -28
  -32
  -36
  -41
  -45
  -50
  -55
  -60
  -65
  -71
  -77
  -83
  -89
  -95
  -102
  -109
  -116
  -124
  -132
  -140
  -149
  -158
  -167
  -177
  -187
  -198
  -209
  -220
Change in working capital, $m
  -5
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
Cash from operations, $m
  -15
  -23
  -27
  -31
  -35
  -39
  -43
  -48
  -53
  -58
  -63
  -69
  -74
  -80
  -86
  -93
  -99
  -106
  -114
  -121
  -129
  -137
  -145
  -154
  -163
  -173
  -183
  -193
  -204
  -216
  -228
Maintenance CAPEX, $m
  0
  -4
  -5
  -6
  -6
  -7
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -14
  -16
  -17
  -18
  -19
  -20
  -22
  -23
  -24
  -26
  -27
  -29
  -31
  -32
  -34
  -36
  -38
  -40
New CAPEX, $m
  -8
  -12
  -12
  -13
  -14
  -15
  -15
  -16
  -17
  -18
  -18
  -19
  -20
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -30
  -32
  -33
  -35
  -36
  -38
  -39
  -41
Cash from investing activities, $m
  -12
  -16
  -17
  -19
  -20
  -22
  -23
  -25
  -27
  -28
  -29
  -31
  -33
  -34
  -37
  -39
  -41
  -43
  -45
  -48
  -50
  -52
  -55
  -57
  -61
  -64
  -67
  -70
  -74
  -77
  -81
Free cash flow, $m
  -27
  -39
  -44
  -50
  -55
  -61
  -67
  -73
  -79
  -86
  -93
  -100
  -107
  -115
  -123
  -132
  -140
  -149
  -159
  -169
  -179
  -189
  -200
  -212
  -224
  -237
  -250
  -264
  -278
  -293
  -309
Issuance/(repayment) of debt, $m
  25
  15
  16
  17
  18
  19
  19
  20
  21
  22
  23
  24
  25
  26
  27
  28
  29
  30
  31
  33
  34
  35
  37
  38
  40
  42
  44
  46
  48
  50
  52
Issuance/(repurchase) of shares, $m
  5
  54
  59
  65
  71
  77
  83
  89
  96
  103
  110
  107
  115
  123
  131
  140
  149
  158
  168
  178
  189
  200
  211
  223
  236
  249
  263
  277
  292
  308
  325
Cash from financing (excl. dividends), $m  
  28
  69
  75
  82
  89
  96
  102
  109
  117
  125
  133
  131
  140
  149
  158
  168
  178
  188
  199
  211
  223
  235
  248
  261
  276
  291
  307
  323
  340
  358
  377
Total cash flow (excl. dividends), $m
  0
  30
  31
  32
  33
  34
  36
  37
  38
  39
  40
  31
  32
  34
  35
  36
  38
  39
  41
  42
  44
  46
  48
  50
  52
  54
  57
  59
  62
  65
  68
Retained Cash Flow (-), $m
  19
  -54
  -59
  -65
  -71
  -77
  -83
  -89
  -96
  -103
  -110
  -107
  -115
  -123
  -131
  -140
  -149
  -158
  -168
  -178
  -189
  -200
  -211
  -223
  -236
  -249
  -263
  -277
  -292
  -308
  -325
Prev. year cash balance distribution, $m
 
  42
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  17
  -29
  -33
  -37
  -42
  -47
  -53
  -58
  -64
  -70
  -76
  -83
  -89
  -96
  -104
  -111
  -119
  -127
  -136
  -145
  -154
  -164
  -174
  -184
  -195
  -206
  -218
  -231
  -244
  -257
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  17
  -26
  -29
  -31
  -33
  -34
  -36
  -36
  -37
  -37
  -36
  -35
  -34
  -32
  -30
  -28
  -26
  -23
  -21
  -18
  -16
  -14
  -11
  -9
  -8
  -6
  -5
  -4
  -3
  -2
Current shareholders' claim on cash, %
  100
  91.2
  83.5
  76.6
  70.5
  65.0
  60.1
  55.6
  51.5
  47.8
  44.4
  41.6
  39.0
  36.5
  34.2
  32.1
  30.1
  28.2
  26.5
  24.9
  23.4
  22.0
  20.6
  19.4
  18.2
  17.1
  16.1
  15.1
  14.2
  13.4
  12.6

AtriCure, Inc., a medical device company, provides atrial fibrillation solutions to hospitals and medical centers in the United States and internationally. The company offers Isolator Synergy System and related radio frequency(RF) ablation devices, which include clamps that are used for ablation during open-heart procedures; ablation and sensing unit, a compact power generator that delivers bipolar RF energy to its clamps, multifunctional pens, and Coolrail linear ablation devices; AtriCure Switch Box, a compact switch box, which offers the technology needed for the dual pulsing electrodes in clamps; and Coolrail linear ablation device, a disposable linear RF ablation device that allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. It also provides Isolator multifunctional pens that enable surgeons to evaluate cardiac arrhythmias; perform temporary cardiac pacing, sensing, and stimulation; and ablate cardiac tissue with the same device. In addition, the company provides COBRA Fusion Surgical Ablation System and EPi-Sense Guided Coagulation System; electrosurgical unit, a compact power generator for use with Fusion ablation products; AFfirm Bipolar Pacing Probe is used to test lesions created in surgically treating the patientÂ’s arrhythmia; cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system that is designed for the left atrial appendage management; nContact RF generator; and Cannula, an access device and conduit for the ablation device. Further, it sells Lumitip dissector to separate tissues to provide access to anatomical structures that are targeted for ablation; and Estech cardiac surgery instruments that are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

FINANCIAL RATIOS  of  AtriCure (ATRC)

Valuation Ratios
P/E Ratio -22.6
Price to Sales 4.8
Price to Book 4.4
Price to Tangible Book
Price to Cash Flow -49.7
Price to Free Cash Flow -32.4
Growth Rates
Sales Growth Rate 19.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -38.5%
Cap. Spend. - 3 Yr. Gr. Rate 21.7%
Financial Strength
Quick Ratio 22
Current Ratio 0.1
LT Debt to Equity 22%
Total Debt to Equity 23.2%
Interest Coverage -16
Management Effectiveness
Return On Assets -11.3%
Ret/ On Assets - 3 Yr. Avg. -11.9%
Return On Total Capital -16.2%
Ret/ On T. Cap. - 3 Yr. Avg. -15.7%
Return On Equity -18.6%
Return On Equity - 3 Yr. Avg. -17%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 71.6%
Gross Margin - 3 Yr. Avg. 71.4%
EBITDA Margin -13.5%
EBITDA Margin - 3 Yr. Avg. -13.6%
Operating Margin -20%
Oper. Margin - 3 Yr. Avg. -18.6%
Pre-Tax Margin -21.3%
Pre-Tax Margin - 3 Yr. Avg. -19%
Net Profit Margin -21.3%
Net Profit Margin - 3 Yr. Avg. -19%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

ATRC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ATRC stock intrinsic value calculation we used $155 million for the last fiscal year's total revenue generated by AtriCure. The default revenue input number comes from 2016 income statement of AtriCure. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ATRC stock valuation model: a) initial revenue growth rate of 13.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ATRC is calculated based on our internal credit rating of AtriCure, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of AtriCure.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ATRC stock the variable cost ratio is equal to 120%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ATRC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 7.5% for AtriCure.

Corporate tax rate of 27% is the nominal tax rate for AtriCure. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ATRC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ATRC are equal to 54.2%.

Life of production assets of 18.9 years is the average useful life of capital assets used in AtriCure operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ATRC is equal to 9.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $168 million for AtriCure - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 33.589 million for AtriCure is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of AtriCure at the current share price and the inputted number of shares is $0.8 billion.

RELATED COMPANIES Price Int.Val. Rating
BSX Boston Scienti 26.89 19.06  sell
MMSI Merit Medical 40.75 1.60  str.sell
DXTR Dextera Surgic 0.280 0.21  sell
ABMD Abiomed 152.14 91.99  sell
EW Edwards Lifesc 113.11 137.96  hold
TFX Teleflex 210.66 86.78  str.sell

COMPANY NEWS

▶ ETFs with exposure to AtriCure, Inc. : August 15, 2017   [Aug-15-17 03:22PM  Capital Cube]
▶ Stock surge on Wall Street pushes these 25 S&P 500 stocks to record highs   [Aug-04-17 07:47AM  American City Business Journals]
▶ AtriCure reports 2Q loss   [Jul-27-17 11:57PM  Associated Press]
▶ AtriCure Announces Hiring of Chief Technology Officer   [Jul-18-17 04:15PM  Business Wire]
▶ ETFs with exposure to AtriCure, Inc. : July 13, 2017   [Jul-13-17 03:30PM  Capital Cube]
▶ AtriCure to Announce Second Quarter 2017 Financial Results   [Jul-06-17 08:00AM  Business Wire]
▶ ETFs with exposure to AtriCure, Inc. : May 12, 2017   [May-12-17 03:40PM  Capital Cube]
▶ Here's Why ArtiCure, Inc. Is Up Double-Digits Today   [May-05-17 12:49PM  Motley Fool]
▶ AtriCure reports 1Q loss   [May-04-17 06:33PM  Associated Press]
▶ AtriCure to Announce First Quarter 2017 Financial Results   [Apr-07-17 04:05PM  Business Wire]
▶ ETFs with exposure to AtriCure, Inc. : April 5, 2017   [Apr-05-17 04:21PM  Capital Cube]
▶ AtriCure founder exits amid board reset   [Mar-24-17 01:50PM  at bizjournals.com]
▶ AtriCure founder exits amid board reset   [01:50PM  American City Business Journals]
▶ AtriCure reports 4Q loss   [04:47PM  Associated Press]
▶ Is Xenith Bankshares Inc (XBKS) Going To Burn These Hedge Funds?   [Dec-20-16 02:07PM  at Insider Monkey]
▶ How Unifi, Inc. (UFI) Stacks Up Against Its Peers   [Dec-14-16 03:21AM  at Insider Monkey]
▶ Do Hedge Funds Love RPX Corp (RPXC)?   [Dec-08-16 10:59AM  at Insider Monkey]
▶ AtriCure Inc. (ATRC) Hedge Funds Are Snapping Up   [09:36AM  at Insider Monkey]
▶ AtriCure Names Sven Wehrwein to its Board of Directors   [Nov-11-16 08:00AM  Business Wire]
▶ AtriCure Announces Upcoming Investor Conference Schedule   [Oct-24-16 04:34PM  Business Wire]
▶ AtriCure to Announce Third Quarter 2016 Financial Results   [Oct-04-16 08:00AM  Business Wire]
▶ AtriCure to Announce Second Quarter 2016 Financial Results   [Jul-11-16 04:05PM  Business Wire]
▶ AtriCure Receives CE Mark for the AtriClip® PRO2 Device   [Jun-29-16 08:00AM  Business Wire]
▶ Several Ohio companies named to Most Trustworthy list   [Jun-15-16 06:25AM  at bizjournals.com]
Stock chart of ATRC Financial statements of ATRC
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.